Timothy J. Miller, Ph.D.

CEO, President and Co-Founder

Timothy Miller is CEO, President and Co-Founder of Forge Biologics, Inc., a VC-backed gene therapy development engine focused on accelerating access to potentially life-saving AAV gene therapies. Prior to founding Forge, Dr. Miller co-founded Abeona Therapeutics, a rare disease gene and cell therapy company. He served as Abeona’s CEO and President from 2012-early 2018, taking the company public in 2015. He is a proven biotech leader with experience in driving gene therapy pipeline development, regulatory strategy, investor relations, M&A activities, licensing, GMP manufacturing, clinical development, and leading stakeholder/shareholder engagement. Dr. Miller has over 20+ years of business development, scientific research, product development and clinical operations expertise, with a focus on transitioning novel gene and cell therapies through pre-clinical and Phase 3 human clinical trials. He is an avid patient-centric drug developer and entrepreneur. Dr. Miller earned degrees in Pharmacology (Ph.D.) and Biology/Molecular Science (M.S. and B.S.) from John Carroll University.

Erandi De Silva, Ph.D.

Co-Founder & Senior Vice President of Product Development

Erandi De Silva is Co-Founder and Senior Vice President of Product Development at Forge Biologics. She is an experienced scientist and entrepreneur, with 10+ years of experience in discovery research, therapeutic development, and partnering across oncology, infectious disease, and gene therapy. Prior to founding Forge, Dr. De Silva held leadership roles in both academic and industry settings, including at Myonexus Therapeutics. She earned a Ph.D. in Molecular Biology from Princeton University, where she was awarded the Procter Fellowship in recognition of exceptional research, and her B.S., with honors, from Stanford University. Dr. De Silva was also a Postdoctoral Research Scientist at Genentech.